Adherence and effectiveness of multicomponent exercise fall prevention programmes across delivery formats in community-dwelling older adults: a systematic review and multilevel meta-analysis.

Arch Gerontol GeriatrMay 20, 2026 (epub)
Clinical ResearchGeriatricsPreventive Medicine / Public Health

Yugui Hua, Yikun Yang, Yaxuan Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and multilevel meta-analysis evaluated the effectiveness of multicomponent exercise programmes for fall prevention in community-dwelling adults aged 60 and older. The analysis included 41 publications with 20,202 participants, revealing that these programmes significantly reduced fall incidence (IRR = 0.776) and risk of experiencing at least one fall (RR = 0.914).

Key findings

  • Multicomponent exercise programmes reduced fall incidence (IRR = 0.776, 95% CI 0.641-0.939).
  • Risk of experiencing at least one fall decreased (RR = 0.914, 95% CI 0.858-0.974).
  • Adherence ≥75% was linked to greater reductions in fall incidence (IRR = 0.501, 95% CI 0.336-0.747).
  • Mean adherence was highest in combined individual and group delivery formats.

Why it matters

Understanding the effectiveness of multicomponent exercise programmes and the role of adherence can help clinicians design better fall prevention strategies for older adults, potentially reducing fall-related injuries and improving overall health outcomes.

Source

PubMed · PMID 42176369

Published in Arch Gerontol Geriatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.